Internal Medicine · Kansas City, KS
NPI
1437411469
Since 2012
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
Kumc Rheumatology Fellowship, 3901 Rainbow Blvd, Ms 2026
Kansas City, KS, 66160
Phone (913) 588-6008
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
467 services
Medicare patients, 2024
186
Average age 70
Drug cost, 2024
$3.3M
1,460 prescriptions
Company payments, 2025
$20.05
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pooja Bhadbhade was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 65 times for 55 patients. In total Pooja Bhadbhade billed 467 services in 24 codes, and Medicare paid $26K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-06-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 65 | 55 | $12.44 | $809 |
| 99214 Office E&M - Established | Facility | 59 | 50 | $68.48 | $4,040 |
| 99214 Office E&M - Established | Office | 57 | 52 | $65.48 | $3,733 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 48 | 43 | $12.53 | $601 |
| 99215 Office E&M - Established | Facility | 42 | 33 | $105.64 | $4,437 |
| 99215 Office E&M - Established | Office | 28 | 22 | $119.63 | $3,350 |
| 99213 Office E&M - Established | Facility | 16 | 16 | $50.77 | $812 |
| 20610 Joint Injection | Facility | 12 | 12 | $39.91 | $479 |
By year: 2022 $20K for 269 services; 2023 $27K for 371 services; 2024 $26K for 467 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pooja Bhadbhade prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 235 prescriptions and refills. In total Pooja Bhadbhade wrote 1,460 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 235 | 651 | 89 | $13K |
| Methotrexate Methotrexate Sodium | 176 | 366 | 53 | $4,704 |
| Prednisone Generic | 104 | 215 | 50 | $938 |
| Enbrel Sureclick Etanercept | 84 | 88 | 14 | $615K |
| Humira(Cf) Pen Adalimumab | 63 | 71 | 11 | $648K |
| Nucala Mepolizumab | 52 | 52 | Under 11 | $448K |
| Actemra Actpen Tocilizumab | 42 | 44 | Under 11 | $128K |
| Tramadol Hcl Generic | 41 | 41 | Under 11 | $345 |
| Cyclobenzaprine Hcl Generic | 26 | 39 | Under 11 | $226 |
| Xeljanz Xr Tofacitinib Citrate | 26 | 26 | Under 11 | $138K |
| Pregabalin Generic | 26 | 40 | Under 11 | $1,110 |
| Simponi Golimumab | 25 | 25 | Under 11 | $143K |
| Rinvoq Upadacitinib | 23 | 23 | Under 11 | $136K |
| Methotrexate Sodium Methotrexate Sodium/Pf | 23 | 37 | Under 11 | $395 |
| Pantoprazole Sodium Generic | 23 | 43 | Under 11 | $145 |
Brand drugs: - claims; generic drugs: 932 claims; opioid claims: 44.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pooja Bhadbhade $20.05 ($20.05 in general payments such as food, travel and fees) from 1 company. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $20.05.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.